Objective: To determine the population-based incidence of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected infants (aged
Methods: The numerator, or number of new cases of disseminated BCG disease, was derived from multicentre surveillance data collected prospectively on infants with a confirmed HIV infection during 2004-2006. The denominator, or total number of HIV-infected infants who were BCG-vaccinated, was derived from population-based estimates of the number of live infants and from reported maternal HIV infection prevalence, vertical HIV transmission rates and BCG vaccination rates.
Findings: The estimated incidences of disseminated BCG disease per 100 000 BCG-vaccinated, HIV-infected infants were as follows: 778 (95% confidence interval, CI: 361-1319) in 2004 (vertical HIV transmission rate: 10.4%); 1300 (95% CI: 587-2290) in 2005 (transmission rate: 6.1%); and 1013 (95% CI: 377-1895) in 2006 (transmission rate: 5.4%). The pooled incidence over the study period was 992 (95% CI: 567-1495) per 100 000.
Conclusion: Multicentre surveillance data showed that the risk of disseminated BCG disease in HIV-infected infants is considerably higher than previously estimated, although likely to be under-estimated. There is an urgent need for data on the risk-benefit ratio of BCG vaccination in HIV-infected infants to inform decision-making in settings where HIV infection and tuberculosis burdens are high. Safe and effective tuberculosis prevention strategies are needed for HIV-infected infants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704039 | PMC |
| http://dx.doi.org/10.2471/blt.08.055657 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disseminated mycobacteriosis secondary to intravenous Bacille Calmette-Guérin (BCG) vaccine.
Natl Med J India
September 2024
Department of Infectious Diseases, Christian Medical College, Ida Scudder Road, Vellore 632004, Tamil Nadu, India.
Bacille Calmette-Guérin (BCG) vaccine has been used increasingly in immunotherapy, including treatment of non-muscle-invasive bladder cancer, as an adjuvant therapy in metastatic prostate cancer and metastatic melanoma. However, systemic infection from inadvertent intravenous (instead of intravesical) injection is uncommon and can have systemic ramifications. We encountered 3 patients with disseminated Mycobacterium bovis infection that ensued after intravenous BCG injection.
View Article and Find Full Text PDFMiliary TB in children and adolescents: a scoping review.
Int J Tuberc Lung Dis
September 2024
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Article Synopsis
- The paper reviews existing literature on miliary tuberculosis (TB) in children and adolescents, focusing on clinical symptoms, diagnosis, treatment, and outcomes.
- A total of 1,883 cases were analyzed, revealing notable statistics including a 30.6% mortality rate, with higher death rates in cases with central nervous system (CNS) involvement and in studies published before 1995.
- There is a lack of consensus on the best diagnostic practices for miliary TB in children, particularly regarding the routine use of lumbar puncture and brain imaging, highlighting the need for more research to fill these gaps.
Invasive Mycobacterium bovis Infection Outside the Genitourinary Tract Following Bacille Calmette-Guerin Therapy for Non-muscle Invasive Bladder Cancer.
Cureus
July 2024
Infectious Disease, Mercy Hospital of Buffalo, Buffalo, USA.
Bladder cancer significantly impacts global health, particularly non-muscle-invasive bladder cancer (NMIBC), which is typically treated with transurethral resection of bladder tumor (TURBT) and intravesical Bacillus Calmette-Guérin (BCG) therapy. While there is evidence that BCG can effectively prevent tumor recurrence and progression, it can cause adverse effects, including disseminated infection, necessitating the exclusion of active tuberculosis and the assessment of immunosuppressive conditions before treatment. We present two cases of disseminated BCG infection.
View Article and Find Full Text PDFInfantile Disseminated Bacille Calmette-Guérin Disease with Hemophagocytosis and Mimicking Juvenile Myelomonocytic Leukemia: A Case Report with Concise Literature Review.
Int J Mycobacteriol
April 2024
Division of Paediatric Haematology and Oncology, Manipal Comprehensive Cancer Care Centre, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Bacille Calmette-Guérin (BCG) is a live-attenuated vaccine routinely administered to newborns to prevent severe forms of tuberculosis (TB) in TB-endemic countries. Disseminated BCG vaccine disease is a classic feature of children with human immunodeficiency virus (HIV) or primary immunodeficiency disorders (PIDs) and is associated with high mortality. We report a case of a 6-month-old infant with disseminated BCG disease and hemophagocytic lymphohistiocytosis mimicking juvenile myelomonocytic leukemia with no demonstrable features of HIV or PID even after extensive laboratory work-up and succumbed to progressive disease.
View Article and Find Full Text PDFEffects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.
J Clin Tuberc Other Mycobact Dis
August 2024
Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.
The bacterial pathogen is responsible for the ongoing global tuberculosis (TB) epidemic. Bacille Calmette-Guérin (BCG), the only currently approved TB vaccine, is successful in preventing disseminated disease in newborns. However, it has a variable efficacy against pulmonary TB in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!